Busulfan induces activin A expression in vitro and in vivo: A possible link to venous occlusive disease

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 3, 2003, Pages 264-274

  Dressel, Dana ^b   Ritter, Christoph A ^b   Sperker, Bernhard ^b   Grube, Markus ^b   Maier, Thorsten ^b   Klingebiel, Thomas ^b   Siegmund, Werner ^b   Beck, James F ^b   Kroemer, Heyo K ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ACTIVIN A; ACTIVIN RECEPTOR; BISINDOLYLMALEIMIDE; BUSULFAN; COMPLEMENTARY DNA; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; LYMPHOCYTE ANTIBODY; MELPHALAN; MESSENGER RNA; METHOTREXATE; PROTEIN KINASE C; THROMBOPLASTIN; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LIVER VEIN OBSTRUCTION; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; PROTEIN INDUCTION; SERUM; VEIN OCCLUSION;

ACTIVIN RECEPTORS; ACTIVINS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BUSULFAN; CELL LINE; CELLS, CULTURED; CYCLOOXYGENASE 2; CYTOKINES; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMATOLOGIC NEOPLASMS; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INHIBIN-BETA SUBUNITS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STEM CELL TRANSPLANTATION;

EID: 0041831258     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00190-5     Document Type: Article

References (41)

1. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992;10:197-214.
2. Richardson P, Guinan E. Hepatic veno-occlusive disease following hematopoietic stem cell transplantation. Acta Haematol 2001;106:57-68.
3. Beschorner WE, Pino J, Boitnott JK, Tutschka PJ, Santos GW. Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection. Am J Pathol 1980;99:369-85.
4. Khalil A, Ciobanu N, Sparano JA, Gucalp R, Dutcher JP, Wiernik PH. Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies. Bone Marrow Transplant 1995;15:93-7.
5. de Magalhaes-Silverman M, Lister J, Rybka W, Wilson J, Ball E. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant 1997;19:777-81.
6. Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, et al. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease [published erratum appears in Biol Blood Marrow Transplant 1998;4:56]. Biol Blood Marrow Transplant 1997;3:261-6.
7. Zander AR, Berger C, Kröger N, Stockschläder M, Krüger W, Horstmann M, et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 1997;3:2671-5.
8. Olavarria E, Kanfer E, Szydlo R, O'Brien S, Craddock C, Apperley J, et al. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience. Br J Haematol 2000;108:769-77.
9. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999;93:4436-40.
10. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996;17:225-30.
11. Schuler U, Schroer S, Kuhnle A, Blanz J, Mewes K, Kumbier I, et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994;14:759-65.
12. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85.
13. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002;22:27-42.
14. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337-43.
15. Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP, de Kretser DM. Evidence for activin A and follistatin involvement in the systemic inflammatory response. Mol Cell Endocrinol 2001;180:155-62.
16. Yasuda H, Mine T, Shibata H, Eto Y, Hasegawa Y, Takeuchi T, et al. Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest 1993;92:1491-6.
17. Chen W, Woodruff TK, Mayo KE. Activin A-induced HepG2 liver cell apoptosis: involvement of activin receptors and smad proteins. Endocrinology 2000;141:1263-72.
18. Ethier JF, Findlay JK. Roles of activin and its signal transduction mechanisms in reproductive tissues. Reproduction 2001;121:667-75.
19. Hilden K, Tuuri T, Erämaa M, Ritvos O. Co-ordinate expression of activin A and its type I receptor mRNAs during phorbol ester-induced: differentiation of human K562 erythroleukemia Cells. Mol Cell Endocrinol 1999;153:137-45.
20. Tuuri T, Erämaa M, Van Schaik RH, Ritvos O. Differential regulation of inhibin/activin alpha- and beta A-subunit and follistin mRNAs by cyclic AMP and phorbol ester in cultured human granulosa-luteal cells. Mol Cell Endocrinol 1996;121:1-10.
21. Nüsing RM, Barsig J. Induction of prostanoid, nitric oxide, and cytokine formation in rat bone marrow derived macrophages by activin A. Br J Pharmacol 1999;127:919-26.
22. Akarasereenont P, Techatraisak K, Thaworn A, Chotewuttakorn S. The induction of cyclooxygenase-2 by 17beta-estradiol in endothelial cells is mediated through protein kinase C. Inflamm Res 2000;49:460-5.
23. Smith RS, Kelly R, Iglewski BH, Phipps RP. The Pseudomonas autoinducer N-(3-oxododecanoyl) homoserine lactone induces cyclooxygenase-2 and prostaglandin E2 production in human lung fibroblasts: implications for inflammation. J Immunol 2002;169:2636-42.
24. Hailer NP, Oppermann E, Leckel K, Cinatl J, Markus BH, Blaheta RA. Prostaglandin E2 induces expression of P-selectin (CD62P) on cultured human umbilical vein endothelial cells and enhances endothelial binding of CD4-T-cells. Transplantation 2000;70:236-40.
25. Bunting S, Moncada S, Vane JR. The prostacyclin - thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull 1983;39:271-6.
26. Ramadan FM, Upchurch GR Jr, Keagy BA, Johnson G Jr. Endothelial cell thromboxane production and its inhibition by a calcium-channel blocker. Ann Thorac Surg 1990;49:916-9.
27. Caughey GE, Cleland LG, Gamble JR, James MJ. Up-regulation of endothelial cyclooxygenase-2 and prostanoid synthesis by platelets. Role of thromboxane A2. J Biol Chem 2001;276:37839-45.
28. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001;86:66-74.
29. Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, et al. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood 2002;99:199-206.
30. Nishimura H, Tsuji H, Masuda H, Nakagawa K, Nakahara Y, Kitamura H, et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997;77:1189-95.
31. Holschermann H, Rascher C, Oelschlager C, Stapfer G, Langenstein A, Staubitz A, et al. Opposite regulation of tissue factor expression by calcineurin in monocytes and endothelial cells. J Immunol 2001;166:7112-20.
32. Mechtcheriakova D, Schabbauer G, Lucerna M, Clauss M, De Martin R, Binder BR, et al. Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001;15:230-42.
33. Ishii H, Takada K, Higuchi T, Sugiyama J. Verotoxin-1 induces tissue factor expression in human umbilical vein endothelial cells through activation of NF-kappaB/Rel and AP-1. Thromb Haemost 2000;84:712-21.
34. Kagawa H, Komiyama Y, Nakamura S, Miyake T, Miyazaki Y, Hamamoto K, et al. Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells. Thromb Res 1998;91:297-304.
35. Yoshizumi M, Tsuji H, Nishimura H, Masuda H, Kunieda Y, Kawano H, et al. Natriuretic peptides regulate the expression of tissue factor and PAI-1 in endothelial cells. Thromb Haemost 1999;82:1497-503.
36. Kim I, Oh JL, Ryu YS, So JN, Sessa WC, Walsh K, et al. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J 2002;16:126-8.
37. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000;101:2144-8.
38. Ritter CA, Sperker B, Grube M, Dressel D, Kunert-Keil C, Kroemer HK. Overexpression of glutathione S-transferase AI-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression. Br J Pharmacol 2002;137:1100-6.
39. Iguchi A, Kobayashi R, Yoshida M, Kobayashi K, Matsuo K, Kitajima I, et al. Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplant 2001;27:1173-80.
40. Jones KL, Brauman JN, Groome NP, de Kretser DM, Phillips DJ. Activin A release into the circulation is an early event in systemic inflammation and precedes the release of follistatin. Endocrinology 2000;141:1905-8.
41. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000;39:155-65.